Literature DB >> 12781708

A longitudinal assessment of autologous neutralizing antibodies in children perinatally infected with human immunodeficiency virus type 1.

Rebeca Geffin1, Cecelia Hutto, Carole Andrew, Gwendolyn B Scott.   

Abstract

The evolution of autologous neutralizing antibodies to sequential human immunodeficiency virus type 1 (HIV-1) isolates was studied in a population of 16 children who were perinatally infected with human immunodeficiency virus type 1. The cohort included seven children with rapid disease progression (RP) and nine who had nonrapid disease progression (NRP). Four of the NRP after 6 months of age harbored viruses that could be neutralized by antibodies found in autologous contemporaneous plasma (titers up to 1:640) while the majority of longitudinally collected viruses from five NRP were resistant to neutralization with contemporaneous plasma. Because of their shorter survival, only five of the RP had studies after 6 months of age; three of the five had neutralizing antibodies to contemporaneous virus isolates and the highest titers were 1:20. The highest titers in RP (up to 1:160) occurred in specimens obtained prior to 6 months of age but these were most likely of maternal origin. Most isolates that were not neutralized by contemporaneous plasma could be neutralized using noncontemporaneous plasma obtained months to years after the virus isolates. These autologous noncontemporaneous neutralizing antibodies persisted for years, had titers that were higher to viruses isolated at younger ages, and were generally more potent in children with NRP than RP. Demonstration of neutralizing antibodies to viruses previously resistant to neutralization by contemporaneous plasma suggests a continuous evolution of virus variants in vivo that are able to escape the effect of neutralizing antibodies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12781708     DOI: 10.1016/s0042-6822(03)00137-5

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  25 in total

1.  Autologous neutralizing antibody to human immunodeficiency virus-1 and replication-competent virus recovered from CD4+ T-cell reservoirs in pediatric HIV-1-infected patients on HAART.

Authors:  Natascha Ching; Karin A Nielsen-Saines; Jaime G Deville; Lian S Wei; Eileen Garratty; Yvonne J Bryson
Journal:  AIDS Res Hum Retroviruses       Date:  2010-05       Impact factor: 2.205

2.  Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses.

Authors:  Steven G Deeks; Becky Schweighardt; Terri Wrin; Justin Galovich; Rebecca Hoh; Elizabeth Sinclair; Peter Hunt; Joseph M McCune; Jeffrey N Martin; Christos J Petropoulos; Frederick M Hecht
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

3.  epitopes immediately below the base of the V3 loop of gp120 as targets for the initial autologous neutralizing antibody response in two HIV-1 subtype B-infected individuals.

Authors:  Haili Tang; James E Robinson; S Gnanakaran; Ming Li; Eric S Rosenberg; Lautaro G Perez; Barton F Haynes; Hua-Xin Liao; Celia C Labranche; Bette T Korber; David C Montefiori
Journal:  J Virol       Date:  2011-07-06       Impact factor: 5.103

4.  Human immunodeficiency virus type 1 variants isolated from single plasma samples display a wide spectrum of neutralization sensitivity.

Authors:  Katharina Skrabal; Sentob Saragosti; Jean-Louis Labernardière; Francis Barin; François Clavel; Fabrizio Mammano
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

5.  Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection.

Authors:  Simon D W Frost; Terri Wrin; Davey M Smith; Sergei L Kosakovsky Pond; Yang Liu; Ellen Paxinos; Colombe Chappey; Justin Galovich; Jeff Beauchaine; Christos J Petropoulos; Susan J Little; Douglas D Richman
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-09       Impact factor: 11.205

6.  HIV-1 evolution in gag and env is highly correlated but exhibits different relationships with viral load and the immune response.

Authors:  Anne Piantadosi; Bhavna Chohan; Dana Panteleeff; Jared M Baeten; Kishorchandra Mandaliya; Jeckoniah O Ndinya-Achola; Julie Overbaugh
Journal:  AIDS       Date:  2009-03-13       Impact factor: 4.177

7.  R5 clade C SHIV strains with tier 1 or 2 neutralization sensitivity: tools to dissect env evolution and to develop AIDS vaccines in primate models.

Authors:  Nagadenahalli B Siddappa; Jennifer D Watkins; Klemens J Wassermann; Ruijiang Song; Wendy Wang; Victor G Kramer; Samir Lakhashe; Michael Santosuosso; Mark C Poznansky; Francis J Novembre; François Villinger; James G Else; David C Montefiori; Robert A Rasmussen; Ruth M Ruprecht
Journal:  PLoS One       Date:  2010-07-21       Impact factor: 3.240

8.  Importance of the V1/V2 loop region of simian-human immunodeficiency virus envelope glycoprotein gp120 in determining the strain specificity of the neutralizing antibody response.

Authors:  Melissa E Laird; Tatsuhiko Igarashi; Malcolm A Martin; Ronald C Desrosiers
Journal:  J Virol       Date:  2008-09-03       Impact factor: 5.103

9.  Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection.

Authors:  Penny L Moore; Nthabeleng Ranchobe; Bronwen E Lambson; Elin S Gray; Eleanor Cave; Melissa-Rose Abrahams; Gama Bandawe; Koleka Mlisana; Salim S Abdool Karim; Carolyn Williamson; Lynn Morris
Journal:  PLoS Pathog       Date:  2009-09-18       Impact factor: 6.823

10.  Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways.

Authors:  Rong Rong; Bing Li; Rebecca M Lynch; Richard E Haaland; Megan K Murphy; Joseph Mulenga; Susan A Allen; Abraham Pinter; George M Shaw; Eric Hunter; James E Robinson; S Gnanakaran; Cynthia A Derdeyn
Journal:  PLoS Pathog       Date:  2009-09-18       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.